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Abstract: Development of bone metastases in patients with advanced cancer is associated with 
skeletal-related events (SREs) such as pathologic fractures, spinal cord compression, the require-
ment for surgery or palliative radiotherapy to bone, and hypercalcemia of malignancy. Skeletal 
morbidity may reduce patient mobility, limit functional independence, and impair quality of life 
(QOL). Proactive management of new or worsening bone pain or motor impairment is crucial 
because of the potential for rapid progression of symptoms. Administration of bisphosphonate 
therapy as a monthly infusion to patients with bone metastases prevents or delays the onset and 
reduces the frequency of SREs and provides clinically meaningful improvements in bone pain 
and QOL. In addition to administration of therapy, the monthly infusion visit allows a dedi-
cated team of healthcare professionals to regularly assess SREs, response to therapy, adverse 
events (AEs), QOL, and adherence to oral medications and supplements. The continuity of care 
that occurs during the monthly infusion visit provides oncology nurses with an opportunity 
to educate patients about effective strategies to manage SREs and AEs. In addition, regular 
interaction provides oncology nurses with an opportunity to recognize and proactively address 
subtle changes in the patients’ medical condition. Using a multidisciplinary medical team also 
eliminates barriers between the various healthcare professionals involved in patient manage-
ment. Consequently, the monthly infusion visit can result in effective patient management and 
improved clinical outcomes in patients with malignant bone disease.
Keywords: adverse events, bisphosphonates, bone metastases, quality of life, skeletal-related 
events, treatment adherence
Introduction
Bone metastases are common in patients with advanced solid tumors, with estimates 
ranging from 20% to 25% for renal cell carcinoma (RCC) and 65% to 75% for breast 
or prostate cancer.1 Moreover, bone lesions are almost inevitable in patients with 
refractory multiple myeloma. Malignant bone disease is associated with considerable 
morbidity and can result in skeletal-related events (SREs) such as pathologic fractures, 
spinal cord compression, the requirement for surgery or palliative radiotherapy to 
bone, and hypercalcemia of malignancy.1 Approximately 50% of patients with bone 
metastases develop SREs, with patients experiencing an average of 1.5 to 4.0 events 
per year, depending on the primary cancer.2,3 Each type of SRE is associated with 
reductions in patient quality of life (QOL), and fractures are also associated with 
decreased survival.4,5
Current options for preventing the development of SREs from bone metastases 
in patients with advanced cancer include chemotherapy, radiotherapy, surgery, and Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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bisphosphonates. Although management of the primary 
malignancy is the cornerstone of therapy, bone metastases 
represent a long-term challenge and often result in symptoms 
despite effective anticancer therapies.1 Bisphosphonates are 
potent inhibitors of osteoclast-mediated bone resorption that 
can lower SRE risks throughout the disease course. Among 
the bisphosphonate agents, pamidronate and zoledronic 
acid are approved for multiple myeloma; pamidronate, 
zoledronic acid, clodronate (outside the United States), and 
ibandronate are approved for breast cancer; and zoledronic 
acid is approved for managing bone lesions secondary to 
a broad range of solid tumors, including prostate and lung 
cancer.6–9 Bisphosphonate therapy not only reduces the risk 
of SREs, but can also decrease bone pain and improve QOL 
in patients with malignant bone disease.1,10
Bisphosphonate therapy is generally administered as a 
monthly intravenous infusion in a hospital or infusion clinic, 
with infusion times ranging from 15 minutes for zoledronic 
acid to 120 minutes for pamidronate and up to 150 minutes 
for ibandronate.6,7,9 In our facility, we take advantage of the 
monthly infusion visit to earmark time for interaction between 
patients and a dedicated team of healthcare professionals. This 
interaction provides the opportunity to regularly assess SREs, 
response to therapy, adverse events (AEs), QOL, and treatment 
adherence. Regular patient interaction is important because the 
effects of cancer and cancer treatments can vary greatly over 
the course of only a few weeks. A monthly infusion visit, such 
as that for bisphosphonates, provides a well-timed window of 
opportunity for proactive patient management.
Personalized treatment plans are becoming an increas-
ingly common approach for managing bone metastases in 
patients with advanced cancer. At King’s College Hospital, 
one of the largest teaching hospitals in London, the Urology 
Department is a major referral center that cares for many 
patients with genitourinary cancers (eg, prostate, kidney, 
bladder, testicular, and penile cancer). Personalized treat-
ment plans are developed for each patient by members of a 
dedicated multidisciplinary team, and suggested treatment 
options are discussed with the patient before the treatment 
plan is finalized. Nurses play a key role in implementing 
treatment plans. Based on the experience at King’s College 
Hospital, personalized treatment plans can improve patient 
care and clinical outcomes of malignant bone disease.
This review article discusses the opportunities afforded 
by the monthly infusion visit for managing bone metastases 
secondary to advanced cancer. Selected case studies dem-
onstrating how the monthly infusion visit can be used to 
improve patient management are also presented.
Benefits of the monthly  
infusion visit
Regular interaction between patients and a dedicated 
healthcare professional team results in more effective 
patient management, and a monthly infusion visit can be 
used for patient follow-up assessments. In a managed-care 
setting, the allocation of nursing resources for infusional 
medicine provides an opportunity for structured follow-up. 
In particular, the continuity of care that occurs during the 
monthly infusion visit establishes a relationship of trust 
between the patient and the oncology nurse, fostering open 
and effective communication. Regularly scheduled visits are 
especially conducive to establishing this relationship because 
of allocated infusion chair occupancy time, in contrast with 
the typical time constraints during regular office visits with 
a physician. In the case of the patient with advanced cancer 
attending for a monthly bisphosphonate infusion visit, the 
oncology nurse can also evaluate the patient’s condition and 
educate the patient regarding the importance of SRE manage-
ment, potential AEs, and the importance of taking calcium 
and vitamin D supplements and remaining hydrated. As a 
result of this regular interaction, the oncology nurse becomes 
the “expert” on a specific patient and will recognize subtle 
changes in the patient that could easily be missed by other 
healthcare professionals. The multidisciplinary nature of 
the medical team also promotes a more effective working 
relationship between the various cancer specialists in the 
infusion clinic. For example, in our facility, the absence of 
formal barriers between team members allows the oncology 
nurse to speak directly to the radiation oncologist about a 
patient needing palliative radiotherapy instead of seeking a 
referral. This helps to reduce treatment delays and can have 
a positive effect on patient care and clinical outcomes. The 
monthly infusion visit can also reduce outpatient appoint-
ments and provide an opportunity for oncology nurses to 
interact with family members and caregivers.
Skeletal-related events
King’s College Hospital has developed a patient-management 
process to leverage regular infusion visits as an opportunity 
to more effectively monitor patients. Early identification of 
new or worsening skeletal morbidity is crucial in patients with 
malignant bone disease, in whom symptoms may progress 
very rapidly. Effective treatment to prevent or delay onset 
and to minimize the severity of SREs plays an important role 
in the supportive care of patients with bone metastases.
In facilities that treat patients with advanced malignancies, 
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that span a large range of cancer types. Bisphosphonates are 
an established component of therapy for patients with bone 
metastases, which are common in most advanced malig-
nancies.11 Among bisphosphonates approved in the UK for 
preventing SREs from bone metastases in patients with breast 
cancer (ie, clodronate, ibandronate, pamidronate, and zole-
dronic acid), zoledronic acid generated the largest reduction 
in SRE risk relative to placebo (Figure 1).10,12–19 Furthermore, 
zoledronic acid significantly reduced the cumulative mean 
incidence of SREs in patients with bone metastases from 
breast cancer (17.8%; P = 0.05 vs pamidronate), prostate 
cancer (35.3%; P = 0.002 vs placebo), or lung cancer or 
other solid tumors (26.9%; P = 0.025 vs placebo).20 These 
results illustrate the benefit of therapy with bisphosphonates 
in patients with malignant bone disease.
As part of each monthly bisphosphonate infusion visit, the 
patient is thoroughly evaluated for the development of new or 
worsening SREs, and effective management strategies should 
be discussed if any are detected. Bone pain is one of the most 
common complications of bone metastases and tends to 
occur throughout the course of the disease.21 Managing bone 
pain generally involves concomitant administration of focal 
radiotherapy and analgesic medications, especially steroids 
and nonsteroidal anti-inflammatory agents, although effec-
tive pain management may require opioids in some   cases.22 
Radiotherapy to bone is standard therapy for palliation of 
malignant bone pain refractory to standard pharmacologic 
interventions. Nonpharmacologic interventions may include 
heat and cold applications, massage, relaxation exercises, and 
therapeutic mattresses.23 Spinal cord compression presents 
initially as back pain and may cause irreversible paraparesis or 
paraplegia if left untreated. Early diagnosis, administration of 
high-dose corticosteroids, and urgent referral for   radiotherapy 
or decompression and spinal stabilization are key for success-
ful rehabilitation.21 Pathologic fractures and hypercalcemia 
of malignancy are relatively late complications of bone 
metastases that may require urgent treatment.21,24 Pathologic 
fractures occur because of loss of bone integrity, thereby 
resulting in increased bone pain and the need for surgical 
intervention.21 Identifying weakened weight-bearing bones 
at high risk for fracture can allow proactive treatment and 
fixation, sparing patients from potentially life-threatening 
fractures. Hypercalcemia of malignancy frequently remains 
undiagnosed and, left untreated, may result in acute renal 
failure, cardiac arrest, or death.24
The beneficial effects of the monthly infusion visit on 
SRE management are illustrated by a recent patient case 
study from King’s College Hospital. A 72-year-old man 
initially presented to his general practitioner with lower 
urinary tract symptoms including nocturia. The patient had 
an abnormal prostate on rectal examination and elevated 
prostate-specific antigen levels (207.3 ng/L). Biopsy results 
revealed prostate adenocarcinoma (Gleason score 5 + 5). 
Based on a multidisciplinary team review of the patient’s 
histology and radiology results, hormone therapy was initi-
ated, and intravenous bisphosphonate therapy was recom-
mended. During a subsequent monthly visit to the nurse-led 
bone support clinic for consideration of bisphosphonate 
therapy, the patient complained to the clinical nurse specialist 
of experiencing pain in his left hip, which he described as a 
“constant ache” when walking that was relieved by sitting. 
The patient was diagnosed with an osteoblastic lesion in 
the peritrochanter-proximal femur that was associated with 
mechanical pain. Subsequent assessment by the clinical nurse 
specialist using the Mirels assessment tool for diagnosis of 
impending pathologic fracture risk resulted in a score of 9 out 
of a possible total of 12, and the patient was estimated to have 
a 33% risk of incurring a pathologic fracture. The clinical 
nurse specialist referred the patient directly to an orthopedic 
surgeon, who admitted the patient the same day under their 
care and performed prophylactic surgical fixation of the 
femoral neck. A radiation oncologist also recommended 
palliative radiotherapy to relieve bone pain.
Response to therapy
The monthly infusion visit also provides healthcare profes-
sionals with an opportunity to regularly assess how the patient 
is responding to the current treatment regimen. Decreases 
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Figure 1 Overall risk of skeletal-related events in patients with bone metastases 
from  breast  cancer  treated  with  bisphosphonates.12–19  Hypercalcemia  was  not 
included as a skeletal-related event (SRe) in this analysis. 
Copyright © 2005. Reproduced with permission of Cochrane Collaboration. Pavlakis 
N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database 
Syst Rev. 2005(3):CD003474.10
Abbreviations: ZOL, zoledronic acid; PAM, pamidronate; iBN, ibandronate; CLO, 
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in the patient’s well-being can be rapidly reported to other 
members of the multidisciplinary team so that adjustments to 
dose and/or schedule as well as modification of the   individual 
components in the treatment regimen can be rapidly imple-
mented to optimize clinical outcomes.
Adverse events
Intravenous therapy is generally administered by the nursing 
staff in most hospitals and infusion centers. As a result, the 
nursing staff play a central role in the safety and comfort of 
patients receiving intravenous therapy. For example, in addi-
tion to ensuring that bisphosphonates are administered in a 
safe and consistent manner, the monthly infusion visit allows 
the oncology nurse to educate the patient about potential AEs 
associated with therapy. Improved communication stemming 
from the regular interaction between the patient and the 
oncology nurse also encourages early reporting of AEs and 
implementation of effective management strategies.
There are key monitoring steps for the administration of 
any intravenous medication that provide important insight 
into the patient’s well-being. For example, before administer-
ing the intravenous infusion, the nursing staff must ensure 
that the patient is adequately hydrated (Table 1).2,25,26 For 
agents cleared by renal filtration, such as bisphosphonates, 
serum creatinine levels should be within acceptable ranges 
to minimize the possibility of renal deterioration. Renal 
impairment is common among the elderly, and many cancer 
therapies can adversely affect renal function. Therefore, the 
monthly visit provides an excellent opportunity for ongoing 
monitoring of renal function. This is also a good time to 
remind patients to take recommended supplements (such as 
calcium or vitamin D for bisphosphonate-treated patients) 
or to follow dietary restrictions.25,26
During an infusion, patients can be counseled on pro-
active AE management. For example, bone pain, nausea, 
fatigue, and fever are the most common AEs reported in 
bisphosphonate-treated patients.27 Acute flu-like symptoms, 
which commonly occur after initial exposure to bisphospho-
nate agents, are related to activation of γδ T cells and the 
subsequent release of pyrogenic cytokines such as tumor 
necrosis factor-alpha and interleukin-6.28 Because acute 
flu-like symptoms are associated with immune system 
activation, their occurrence may be predictive of response 
to therapy. These symptoms are generally mild, transient, 
and manageable with standard analgesic medications.27,29 
Because all intravenous bisphosphonates are associated 
with dose- and infusion-rate–dependent effects on renal 
function, serum creatinine should be assessed before each 
infusion. The baseline serum creatinine clearance rate should 
be measured before the first intravenous bisphosphonate 
infusion, and the dose adjusted if needed. Treatment 
should be administered in no less than the recommended 
infusion times. Shorter infusion times and higher doses 
of bisphosphonates may increase the risk of renal AEs.27,29 
Osteonecrosis of the jaw (ONJ), characterized by exposed 
bone in the maxillofacial area that occurs spontaneously or 
after dental surgery in the absence of metastatic disease in 
the jaw or osteoradionecrosis, with no evidence of healing 
after 6 weeks of appropriate dental care, has been reported 
as an uncommon AE in patients receiving complex treatment 
regimens including bisphosphonates. Approximately 1% of 
patients in the advanced cancer setting and 0.2% of patients 
in the adjuvant cancer setting develop ONJ.30–34 Implement-
ing proactive dental surveillance and completing necessary 
dental work before administering bisphosphonate therapy 
reduces the incidence of ONJ, and early identification and 
management of this condition may improve healing.35,36 The 
monthly visit allows follow-ups on dental health issues. 
Recommended supportive care measures for managing 
AEs associated with bisphosphonate therapy are presented 
in Table 1.2,25,26
Quality of life
Inadequate pain management may result in reductions in 
patient mobility, functional independence, and QOL. Interac-
tions during the monthly infusion visit allow the oncology 
nurse to conduct regular QOL assessments that monitor the 
patient’s well-being and ability to function during daily 
activities. Any QOL deterioration or performance status 
reduction should prompt evaluation of whether modification 
of palliative therapy is necessary.
Oncology nurses can use various instruments, including 
QOL questionnaires and patient diaries, to assess the QOL 
of patients with advanced cancer. The European Organisa-
tion for Research and Treatment of Cancer (EORTC) QOL 
Questionnaire Group Bone Metastases Module (QLQ-BM22) 
is a newly developed QOL questionnaire that captures symp-
toms and morbidities specific to bone metastases that were 
not included in the previous QOL questionnaire (EORTC 
  QLQ-C30).37,38 The new questionnaire consists of 22 items, 
rated on a scale from 1 (not at all) to 4 (very much), that 
evaluate a patient’s experience during the previous week 
regarding painful sites and pain characteristics, as well as 
functional limitations and psychosocial concerns associated 
with pain (Table 2).38 The EORTC QLQ-BM22, which is cur-
rently undergoing additional clinical validation, will enable   Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Table 1 Guidelines for administering bisphosphonate therapy
Assessment information checklist25
• Height and posture
• weight
•   Serum creatinine and corrected serum creatininea  
(0.6–1.3 mg/dL or 70–120 µmol/L)
• Hydration status
  – Signs and symptoms of dehydration
­ –­Adequate­fluid­intake­(2–3­L/day)b
  – Diarrhea or vomiting in previous 24 hr
• Pain and analgesic assessment
  – Severity
  – Site
  – Type of pain
• Concomitant medications
  – Dose and schedule
  – Calcium and vitamin D supplementation
• Concomitant treatments (eg, radiotherapy, chemotherapy)
• Mobility and activity
• Oral condition
• Discussion of any adverse events since last visit
•   Determination of whether the patient has  
experienced any new skeletal-related events
  – effectiveness of treatment from patient’s viewpoint
Observations for a patient diary25
•­During­the­first­5­days­after­each­infusion
  – Urinary frequency
  – Fever/malaise
  – Other symptoms
• Ongoing symptoms
  – Pain level (vAS or BPi)
  – Locations of any bone pain
  – Analgesic use or other medications
  – Physical activity or ability to move
Patient education – side effects25
• Possible adverse events
  –   Flu-like symptoms (after initial infusion) and skeletal pain  
(acetaminophen [paracetamol] can be administered  
prophylactically)
  –   Renal function deterioration (serum creatinine  
and creatinine clearance)
  –   Osteonecrosis of the jaw (spontaneously or after  
dental procedure) – uncommon
• what to do when side effects occur
 –  ensure availability of therapy for common adverse events
  –   Advise patients of adverse events for which they should contact the 
healthcare team
  –   ensure patient’s accessibility to the hospital
­ –­­ Reassure­patients­who­experience­flu-like­symptoms­that­the­
symptoms will be less severe after each subsequent infusion and will 
not likely occur after the second or third infusion
Supportive care measures26
• Acute-phase reaction: Assess dehydration and electrolyte levels
  –   Nausea/vomiting: Administer antiemetics (eg, thiethylperazine or 
prochlorperazine) and/or mild analgesics (eg, acetaminophen) as 
necessary
  –   Fever: Monitor vital signs and nutritional status; administer 
antipyretics­(eg,­acetaminophen)­prophylactically­for­the­first­
24­hours­after­the­first­and­second­infusions­and­then­as­needed;­
admit patient for persistent fever
  –   Diarrhea: Monitor vital signs and nutritional status; administer 
antidiarrheals (eg, loperamide)
­ –­­ Acute-phase­reaction­tends­to­occur­after­the­first­bisphosphonate­
infusion and typically does not occur or is less severe with subsequent 
doses
• Anemia: Red blood cell transfusion and/or erythropoietin
•   Myalgia/arthralgia: Administer analgesics (eg, acetaminophen) 
or­nonsteroidal­anti-inflammatory­agents­(eg,­ibuprofen),­unless­
contraindicated
•­­ Constipation:­Administer­stool­softeners;­maintain­adequate­fluid­intake;­
modify­diet;­increase­fiber­intake
• Headache: Administer analgesics (eg, acetaminophen)
• Anorexia: Nutritional supplements, appetite stimulants
•   edema lower limb: Maintain elevation of extremities; use compression 
stockings, if needed
•­­ Practical­assistance:­Patients­may­benefit­from­arrangements­for­
assistance with their mobility at home, housekeeping, transportation, etc
•   Psychosocial distress: Patients may experience emotional distress 
related to their situation and should be referred for professional 
evaluation if distress levels are found to be too high
Notes: aCorrected for age, weight, and sex; bUnless­patient­is­on­restricted­fluid­intake.
Copyright © 2009. Reproduced with permission from Oncology Nursing Society. Fitch M, Maxwell C, Ryan C, Lothman H, Drudge-Coates L, Costa L. Bone metastases from 
advanced cancers: clinical implications and treatment options. Clin J Oncol Nurs. 2009;13(6):701–710.2
bone-metastasis–related QOL outcomes to be compared 
across treatment regimens and will assist in selecting appro-
priate treatment interventions.
Use of a patient diary for recording pain scores, changes 
in mobility, and AEs may also facilitate interaction between 
the patients and the oncology nurse during the monthly infu-
sion visit.25 As part of an ongoing record of patient progress, 
information should be recorded in the patient diary before 
or during each infusion visit and should be compared with 
baseline information obtained before treatment was initiated. 
Research-based evidence highlights the importance of using 
a patient diary for assessing and managing pain. Regular use 
of a patient diary heightens a patient’s awareness of pain pat-
terns, guides pain management behavior, confers a sense of 
control over pain, and facilitates communication with health-
care professionals.23,39 Use of a patient diary may also assist 
patients in recognizing early, more subtle benefits of therapy, 
resulting in improved treatment adherence. Patient diaries 
may also help oncology nurses to identify when appropriate 
interventions are necessary to enhance QOL.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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During the monthly infusion visit, the oncology nurse 
can recommend several interventions to reduce pain and 
maintain QOL. As previously described, managing bone 
pain generally involves administering analgesic medica-
tions or palliative radiotherapy to patients with refractory 
bone pain. Bisphosphonate therapy is also associated with 
clinically meaningful palliation of bone pain. Administering 
zoledronic acid as a monthly infusion to patients with bone 
metastases from breast cancer is associated with reduced 
pain and improved QOL.40,41 In a cross-over study wherein 
zoledronic acid was administered to patients with cancer, 
either in a hospital or community setting, pain and QOL 
were prospectively evaluated by trained nurses. Analysis of 
Brief Pain Inventory scores revealed that zoledronic acid 
improved scores from baseline for composite pain, worst 
pain, and average pain; zoledronic acid also reduced the 
overall extent to which pain interfered with general activi-
ties and walking ability (N = 101; P # 0.05; Figure 2A).40 
Significant improvements from baseline in global health and 
in physical, social, and emotional functioning, as assessed 
using EORTC QLQ-C30, were also observed in patients 
receiving zoledronic acid therapy (N = 101; P , 0.05 vs 
baseline; Figure 2B).40 The observed QOL improvements 
suggest that administration of zoledronic acid as a monthly 
intravenous infusion has the ability to maintain patient mobil-
ity and functional independence. A Cochrane meta-analysis 
of 30 randomized clinical studies of bisphosphonates for 
relief of pain secondary to bone metastases recommended 
their use for diffuse, painful metastases, especially when 
analgesics with or without radiotherapy failed to provide 
adequate pain relief or produced unacceptable adverse drug 
reactions (N = 3682).42 Indeed, bisphosphonate therapy 
should be considered for pain management in all patients 
with bone metastases because they are the only approved 
class of supportive pharmacotherapy capable of relieving 
pain and affecting the underlying pathophysiology of bone 
metastases–malignant osteolysis.2 Oncology nurses can also 
educate patients about how to modify their lifestyle to reduce 
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Figure  2  A)  effect  of  monthly  infusion  of  zoledronic  acid  on  pain.  *P  ,  0.05; 
†P , 0.005 versus baseline. B) effect of monthly infusion of zoledronic acid on quality 
of life. *P , 0.05 versus baseline. 
Abbreviations: BPi, Brief Pain inventory; eORTC, european Organisation for Research 
and  Treatment  of  Cancer.  Copyright  ©  2005.  Reproduced  with  permission  from 
Nature Publishing Group. wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid 
significantly­improves­pain­scores­and­quality­of­life­in­breast­cancer­patients­with­bone­
metastases: a randomised, crossover study of community vs hospital bisphosphonate 
administration. Br J Cancer. 2005;92(10): 1869–1876.40
Table 2 issues included in the Bone Metastases Quality of Life 
Questionnaire (eORTC QLQ-BM22)
Symptom scales
Painful sites
  1. Back
  2. Leg(s) or hip(s)
  3. Arm(s) or shoulder(s)
  4. Chest or ribs
  5. Buttocks
Pain characteristics
  6. Constant pain
  7. intermittent pain
  8. Pain not relieved by medications
Functional scales
Functional interference
  9. Pain while lying down
10. Pain while sitting
11. Pain when trying to stand up
12. Pain while walking
13. Pain with activities such as bending or climbing stairs
14. Pain with strenuous activity
15. Pain interfered with your sleeping 
16. Modify your daily activities
Psychosocial aspects
17. Felt isolated from those close to you
18. worried about loss of mobility 
19. worried about becoming dependent on others
20. worried about your health in the future
21. Felt hopeful your pain will get better
22. Felt positive about your health
Copyright  ©  2009.  Reproduced  with  permission  from  elsevier.  Chow  e,  Hird  A, 
velikova G, et al. The european Organisation for Research and Treatment of Cancer 
Quality  of  Life  Questionnaire  for  patients  with  bone  metastases:  the  eORTC 
QLQ-BM22. Eur J Cancer. 2009;45(7):1146–1152.38
Abbreviation: eORTC, european Organisation for Research and Treatment of Cancer.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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the risk of a fracture (eg, incorporating modifications in their 
environment to prevent falls).25,26
A recent case study illustrates how incorporating individ-
ual patient preferences into management plans for malignant 
bone disease may preserve QOL. Two patients with RCC pre-
sented with bone metastases on the lower leg; surgical ampu-
tation was recommended based on an orthopedic evaluation. 
The first patient underwent leg amputation and subsequently 
required ambulatory support for the rest of his life. The 
second patient, a 68-year-old woman with bone metastases 
on the right tibia, refused amputation and instead elected to 
receive radiotherapy, zoledronic acid, dexamethasone, and 
opioid analgesics. After 4 weeks, she reported reduced pain 
and was able to walk with the assistance of crutches instead of 
a walking frame. After 12 weeks, the patient’s N-telopeptide 
of type I collagen levels normalized, indicating a reduction 
in malignant osteolysis. Notably, the patient sustained no 
fractures and did not require increased analgesic use before 
succumbing to her disease approximately 7 months after ini-
tiation of radiotherapy and zoledronic acid.43 The potential of 
radiotherapy plus zoledronic acid to restore function in bone 
affected by aggressive tumors is an important consideration 
for preserving mobility and QOL in patients with limited 
therapeutic options.
Treatment adherence
One concern with long-term therapies is patients’ ongoing 
adherence to dosing protocols. Indeed, this is especially chal-
lenging when there is limited tracking of treatment effects. 
For example, because bisphosphonate therapy is a preventive 
intervention in patients with bone metastases, patients may 
lose interest in taking their medication because of the lack 
of any outward sign of benefit. Administering bisphospho-
nate therapy as an intravenous infusion improves treatment 
adherence versus oral therapy and provides an assurance that 
the patient is receiving the prescribed agent.44 The oncology 
nurse can also educate the patient about the relationship 
between treatment adherence, improved clinical outcomes, 
and prevention of SREs.
Numerous studies have demonstrated that both overall 
compliance and persistence with oral bisphosphonate therapy 
are poor among women with osteoporosis. Extending the dos-
ing interval increased adherence; however, gains remained 
suboptimal. Notably, low compliance and persistence rates 
consistently resulted in increased fracture rates.45 Intravenous 
bisphosphonate therapy is generally associated with improved 
adherence compared with oral bisphosphonate therapy in 
patients with advanced cancer. A retrospective analysis of 
a German health-claims database reported that persistency 
rates (defined as continuous prescription refill without an 
interruption lasting longer than 30 days) were significantly 
higher with intravenous bisphosphonates (92%) compared 
with oral bisphosphonates (36.4%; P = 0.0012).44 A pro-
spective study of 79 women with metastatic breast cancer 
conducted in the United Kingdom reported that although self-
reported adherence to oral bisphosphonate therapy was high, 
21% of patients had chosen not to take their medications at 
some time. Twenty-four percent of patients expressed dissat-
isfaction with constraints associated with oral bisphosphonate 
administration, especially the time required to remain upright 
after taking their medication. In contrast, an overwhelming 
majority of patients receiving intravenous bisphosphonate 
therapy were generally satisfied with the frequency (91%) 
and the convenience (88%) of their medications, especially 
when administered concurrently with chemotherapy.46
Adherence to intravenous bisphosphonate therapy is 
associated with improved clinical outcomes among patients 
with advanced cancer. Analysis of a national medical claims 
database of patients with solid tumors and bone metastases 
revealed that administering zoledronic acid according to the 
recommended continuous dosing regimen (4 mg every 3 to 
4 weeks) provided the greatest protection against SREs (0.16 
SREs/month vs 0.43 SREs/month with no bisphosphonate 
therapy). Patients who received zoledronic acid according to 
less frequent dosing schedules were only partially protected 
against SREs (0.31 SREs/month; Table 3).47 Administration 
of zoledronic acid according to the recommended dosing 
schedule was also associated with a significantly longer 
duration of follow-up (17.11 months) compared with admin-
istration according to nonrecommended dosing schedules 
(9.93 months) or no treatment (8.68 months; P , 0.001).47 
Therefore, administering zoledronic acid based on the rec-
ommended continuous dosing schedule reduced the skeletal 
Table 3 effect of zoledronic acid on skeletal morbidity rate in 
patients with solid tumors and bone metastases
ZOL schedule  
(patients, n)
Skeletal morbiditya,  
SREs/mo
Follow-up  
durationb, mo
None (3038) 0.43 8.68
Any (1508) 0.29 12.2
On-label 0.16 17.11
Off-label 0.31 9.93
Notes: aP # 0.05 for each comparison; bP , 0.001 for each comparison.
Copyright© 2008. Adapted with permission from John wiley and Sons. Hatoum HT, 
Lin SJ, Smith MR, Barghout v, Lipton A. Zoledronic acid and skeletal complications in 
patients with solid tumors and bone metastases: analysis of a national medical claims 
database. Cancer. 2008;113(6):1438–1445.47
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morbidity rate and increased follow-up duration, suggesting 
increased survival among patients with malignant bone 
disease.
Regular interaction between the patient and the oncol-
ogy nurse in the infusion center fosters adherence to therapy 
protocols. The oncology nurse is uniquely positioned to 
educate the patient and his/her caregivers and to reinforce 
the importance of continuous therapy for managing meta-
static bone disease and associated SREs. Patient education 
is especially important because poor adherence to bispho-
sphonate therapy is frequently caused by the patient not 
understanding how the medication works or why it needs to 
be taken on a continuous basis. The oncology nurse should 
explain that prematurely discontinuing bisphosphonate 
therapy leaves the patient at risk for painful and debilitating 
SREs, which reduce functional independence and impair 
activities of daily living.48 By highlighting the benefits of 
administering bisphosphonates according to recommended 
dosing schedules and enacting established supportive care 
protocols to ensure patient safety and comfort, oncology 
nurses may increase patients’ persistence with and adherence 
to bisphosphonate therapy.
Clinical outcomes
An infusion visit also allows for discussion of the latest 
clinical news about the patient’s regimen, such as identifica-
tion of new potential risks or benefits. Patients often enquire 
about new data from the common media or information on 
their current medications that their family members access 
on the Internet. For example, bisphosphonates have been in 
the news recently because of an association with improved 
clinical outcomes among patients with early or advanced 
cancer. In the AZURE trial, the effects of adding zoledronic 
acid to standard neoadjuvant and adjuvant chemotherapy 
for early breast cancer are being evaluated. In the subgroup 
of patients who received neoadjuvant chemotherapy, adding 
monthly zoledronic acid reduced residual invasive tumor size 
compared with chemotherapy alone (P = 0.006; n = 205).49 
The pathologic complete response rate (breast and axilla) was 
also higher among patients treated with zoledronic acid plus 
chemotherapy (11.7%) compared with chemotherapy alone 
(6.9%; P = 0.146). Several studies reported that zoledronic 
acid improved overall survival among patients with various 
types of advanced cancer including multiple myeloma, blad-
der cancer, and lung cancer.50–52 In the largest of these studies, 
the Medical Research Council Myeloma IX study, zoledronic 
acid significantly improved overall survival (P =  0.0118) and 
progression-free survival (P =  0.0179) versus clodronate 
in patients with newly diagnosed multiple myeloma 
(N = 1960).50 Furthermore, subset analyses of 2 phase III 
clinical studies revealed that zoledronic acid prolonged 
survival compared with placebo among patients with solid 
tumors who had high baseline N-telopeptide of type I col-
lagen levels.53,54 Survival benefits appeared to be independent 
of SRE prevention, suggesting that zoledronic acid may 
improve survival via anticancer activity.50,53,54
Recently, administering zoledronic acid with endocrine 
therapy for early breast cancer also resulted in apparent 
anticancer benefits. In this low-disease-burden setting, 
zoledronic acid was administered every 6 months. In the 
ABCSG-12 study, adding zoledronic acid to adjuvant 
endocrine therapy resulted in a relative reduction of 36% 
in the risk of disease progression compared with endocrine 
therapy alone in premenopausal women with early breast 
cancer (hazard ratio [HR] = 0.64; P = 0.01; N = 1803).55 
Patients treated with zoledronic acid experienced fewer 
events of locoregional and distant recurrence, bone 
metastases, and disease in the contralateral breast. In the 
ZO-FAST (N = 1065) and Z-FAST (N = 602) studies, 
immediate addition of zoledronic acid to adjuvant letrozole 
reduced disease recurrence in postmenopausal women with 
early breast cancer (HR = 0.59 [P = 0.0176] and HR = 0.8 
[P = not significant] for immediate vs delayed zoledronic 
acid, respectively).34
Moreover, recent retrospective database analyses revealed 
that administration of bisphosphonates for postmenopausal 
osteoporosis is associated with lower rates of invasive breast 
cancer.56–58 Therefore, discussion of these new results of 
bisphosphonate therapy may also provide a positive outlook 
for patients who may be experiencing challenges with their 
concomitant anticancer therapies.
Conclusion
Administering bisphosphonate therapy as a monthly intra-
venous infusion provides healthcare professionals with an 
opportunity to adopt a holistic approach toward managing 
malignant bone disease in patients with advanced cancer. 
During each infusion visit, healthcare professionals can 
assess SREs, response to therapy, AEs, QOL, and treatment 
adherence. Proactive management of new or worsening SREs 
is extremely important in patients with malignant bone dis-
ease because symptoms may progress very rapidly. Skeletal 
morbidity may limit patient mobility, reduce functional inde-
pendence, and impair QOL. Effective management of SREs 
plays an important role in the supportive care of patients with 
bone metastases. Bisphosphonates prevent or delay the onset Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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and decrease the frequency of SREs, thereby reducing bone 
pain and improving QOL. Administering   bisphosphonate 
therapy as an intravenous infusion is also associated with 
improved treatment adherence and clinical outcomes com-
pared with oral bisphosphonate therapy in patients with 
malignant bone disease.50
Regular interaction between patients and a dedicated team 
of healthcare professionals results in effective management 
of bone metastases. The continuity of care that occurs dur-
ing the monthly infusion visit establishes trust between the 
patient and the oncology nurse, leading to more open and 
effective communication. As a result of regular interaction, 
the oncology nurse is uniquely positioned to recognize and 
respond to subtle changes in the patient’s condition. The 
monthly infusion visit also provides the oncology nurse with 
an opportunity to educate the patient about effective strategies 
to manage SREs and AEs and to maintain QOL. Incorpora-
tion of patient preferences into personalized treatment plans 
is likely to improve patient care and clinical outcomes of 
malignant bone disease.
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